Table 3. Univariate Kaplan-Meier analysis of the risk of progression or death related to pathological and molecular variables in patients with brain tumors.

		Progression		Overall survival
		HR (95% CI)	p	HR (95% CI)	p
Total Sample (n = 132)
EPB41L3 meth	No	Ref.		Ref.
	Yes	1.52 (0.91, 2.56)	0.109	1.68 (1.00, 2.82)	0.047
RASSF2 meth	No	Ref.
	Yes	1.35 (0.48, 3.80)	0.572	1.71 (0.77, 3.80)	0.184
TSP-1 meth	No	Ref.		Ref.
	Yes	0.66 (0.42, 1.04)	0.074	0.61 (0.38, 0.97)	0.037
Astrocytic tumours (n = 103)
EPB41L3 meth	No	Ref.		Ref.
	Yes	1.58 (0.87, 2.89)	0.130	2.45 (1.33, 4.49)	0.003
RASSF2 meth	No	Ref.		Ref.
	Yes	1.52 (0.36, 6.47)	0.567	1.30 (0.46, 3.66)	0.616
TSP-1 meth	No	Ref.		Ref.
	Yes	0.73 (0.45, 1.20)	0.210	0.72 (0.43, 1.21)	0.220
Oligodendroglial tumours (n = 29)
EPB41L3 meth	No	Ref.		Ref.
	Yes	2.11 (0.65, 6.82)	0.203	1.03 (0.37, 2.89)	0.959
RASSF2 meth	No	Ref.		Ref.
	Yes	1.86 (0.34, 10.21)	0.467	4.63 (1.03, 20.86)	0.029
TSP-1 meth	No	Ref.		Ref.
	Yes	0.52 (0.16, 1.69)	0.273	0.42 (0.14, 1.24)	0.107

CI, confidence interval; HR: hazard ratio; meth, methylation; Ref., reference value